Scientists Discover an Unexpected New Antibiotic Source — the Human Nose

The human body is home to trillions of microorganisms — bacteria, fungi, archaea, and viruses — that collectively form the microbiome. Most research attention has focused on the gut microbiome, but increasingly, scientists are turning to other body sites. The nasal cavity, it turns out, hosts a surprisingly complex microbial community, and at least one member of that community has been producing an antibiotic that science only recently noticed.

The Discovery

A research team studying the nasal microbiome identified a strain of Staphylococcus epidermidis — a common, generally harmless bacterium found on human skin and mucous membranes — that produces a compound with potent antimicrobial activity. The compound, which the researchers named epifadin, belongs to a structural class not previously characterized in this bacterial species.

What makes the finding significant is not just the novelty of the compound but where it was found. S. epidermidis is one of the most thoroughly studied bacteria in existence, precisely because it is so common in clinical settings and can cause opportunistic infections in immunocompromised patients. That such a well-studied organism could still be hiding an uncharacterized antibiotic compound illustrates how much we do not yet know about microbial biochemistry — even in our own bodies.

What Epifadin Does

In laboratory tests, epifadin demonstrated activity against a range of bacterial pathogens, including strains of Staphylococcus aureus (including MRSA, methicillin-resistant S. aureus), Streptococcus species, and several gram-negative organisms. The minimum inhibitory concentrations (MICs) observed were in a range consistent with therapeutic relevance — meaning the compound kills or inhibits bacteria at concentrations that could, in principle, be achieved in living tissue without excessive toxicity.

Mechanistic studies suggest epifadin acts by disrupting bacterial membrane integrity, though the precise molecular target is still under investigation. This mode of action is shared by several clinically used antibiotics (polymyxins, daptomycin), and while it carries a risk of toxicity to human cells, compounds with this mechanism can often be optimized for selectivity during drug development.

Why the Nose?

The nasal cavity is an ecological battleground. It is one of the primary entry points for respiratory pathogens including S. aureus, Streptococcus pneumoniae, and various viruses. The resident microbiome of the nasal cavity is therefore under constant competitive pressure from incoming pathogens — an environment that should, in theory, select for microorganisms capable of producing antimicrobial compounds.

This ecological logic — that the human body's own microbial communities have evolved weapons against pathogens over millions of years — is the basis for a broader research strategy sometimes called human microbiome mining. Rather than searching soil bacteria or marine organisms for novel antibiotics (the traditional approach), researchers look at microorganisms that have co-evolved with human pathogens in direct contact environments.

The nose is particularly attractive for this strategy because: it has high exposure to respiratory pathogens; the resident microbiome is relatively small and well-characterized compared to the gut; and collection of samples is non-invasive. Several previous discoveries have come from nasal isolates, including lugdunin (from S. lugdunensis, identified in 2016), which also showed anti-MRSA activity.

The Antibiotic Resistance Context

The discovery matters beyond its intrinsic scientific interest because of where the antibiotic development pipeline stands. The World Health Organization designates antibiotic-resistant infections as one of the top ten global public health threats. MRSA alone kills an estimated 100,000 people per year globally. Gram-negative bacteria resistant to all available antibiotics (pandrug-resistant strains) are increasingly reported from intensive care units worldwide.

Meanwhile, the antibiotic development pipeline has been nearly dry for decades. Most antibiotic classes in clinical use today were discovered between the 1940s and the 1980s. Since then, truly new chemical classes of antibiotics have been extremely rare — teixobactin (2015) and a handful of others represent the exceptions. Pharmaceutical companies largely exited the antibiotic development business in the 1990s due to the economics: antibiotics are taken for short courses and patients recover, making them far less profitable than drugs for chronic conditions.

Against this backdrop, any new lead compound with a novel structure and demonstrated activity against resistant pathogens attracts serious scientific attention.

From Discovery to Drug: The Long Road

It is important to be precise about what this discovery is and is not. Epifadin is a lead compound — a promising starting point for drug development. It is not a drug. The path from a promising compound isolated from bacteria to an approved antibiotic medication typically takes 10–15 years and costs hundreds of millions of dollars, with a high attrition rate at each stage.

The key hurdles ahead include:

• Toxicity profiling: The compound must be tested in cell cultures and animal models to determine whether it kills bacteria selectively without damaging mammalian cells at therapeutic concentrations.
• Pharmacokinetics: Can the compound be absorbed, distributed to infected tissues, and cleared from the body at rates compatible with dosing schedules? Many otherwise promising compounds fail here.
• Resistance development: Bacteria can evolve resistance to any antibiotic given sufficient exposure. How rapidly do target organisms develop resistance to epifadin, and through what mechanisms?
• Synthesis and supply: Can the compound be produced in sufficient quantities for clinical use? Natural product antibiotics often have complex structures that make total chemical synthesis difficult; fermentation-based production may be necessary.
• Clinical trials: Phases I, II, and III trials must demonstrate safety and efficacy in humans before regulatory approval.

None of these hurdles are impossible, but they are all real. Many compounds that looked excellent in early testing have failed at later stages.

What Makes This Find Particularly Notable

Beyond the clinical potential, the discovery raises an intriguing evolutionary question. S. epidermidis lives in peaceful coexistence with its human host under normal conditions. Why does it produce an antibiotic at all? The most likely answer is that epifadin serves a competitive function within the nasal microbiome — allowing the producing strain to compete for space and nutrients against other nasal colonizers, including pathogenic species.

This competitive dynamic may explain why the nasal microbiome has been such a productive hunting ground: evolution has already done much of the optimization work. Compounds shaped by millions of years of competition against the same pathogens that threaten human health are a different starting point than compounds derived from soil bacteria that have never encountered S. aureus.

Conclusion

The identification of epifadin from nasal S. epidermidis is a genuine scientific finding with real translational potential. It adds to growing evidence that the human microbiome is an underexplored reservoir of novel antimicrobial chemistry. Whether epifadin itself becomes a clinical antibiotic depends on many factors that will take years to resolve. What is already clear is that looking at our own microbial inhabitants — organisms that have co-evolved with human pathogens in the most direct possible way — is a productive strategy for addressing one of medicine's most urgent problems.